Company Overview of Alcobra Ltd.
Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.
Azrieli Triangle Building
132 Derech Menachem Begin
Tel Aviv, 6701101
Founded in 2008
Key Executives for Alcobra Ltd.
Chief Executive Officer, President and Director
Total Annual Compensation: $647.0K
Chief Financial Officer and Chief Operating Officer
Total Annual Compensation: $511.0K
Chief Commercial Officer
Total Annual Compensation: $511.0K
Chief Medical Officer
Total Annual Compensation: $464.0K
Senior Vice President of Regulatory Affairs
Total Annual Compensation: $240.0K
Compensation as of Fiscal Year 2015.
Alcobra Ltd. Key Developments
Alcobra Receives European Orphan Drug Designation for Metadoxine in Fragile X Syndrome
Jul 19 16
Alcobra Ltd. announced that the European Commission (EC) has granted Orphan Drug designation to Metadoxine for the treatment of Fragile X Syndrome within the European Union. EC Orphan Drug designation is granted to drugs that are intended for the treatment of life threatening or chronically debilitating rare diseases where no satisfactory therapeutic options exist. The designation provides sponsors with development and commercial incentives, including 10 years of market exclusivity, prioritized consultation by the European Medicines Agency on the development of the drug, including clinical studies, and certain exemptions from, or reductions in, regulatory fees. In 2013, the U.S. Food and Drug Administration (FDA) granted orphan drug status in the United States to Metadoxine for the treatment of Fragile X Syndrome, and in 2015, the FDA granted Fast Track designation to proprietary Metadoxine Extended Release (MDX) for Fragile X Syndrome. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that demonstrate the potential to address unmet medical needs in serious or life-threatening diseases or conditions. Currently, there are no approved medications in the United States or Europe for Fragile X Syndrome.
Alcobra Ltd. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 10:15 AM
Jul 7 16
Alcobra Ltd. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 10:15 AM. Venue: Le Parker Meridien, New York, New York, United States.
Alcobra Ltd., Annual General Meeting, Jul 19, 2016
Jun 8 16
Alcobra Ltd., Annual General Meeting, Jul 19, 2016, at 10:00 Israel Standard Time. Location: Beit Zion", 41-45 Rothschild Blvd., 8th Fl Tel Aviv 6578401 Israel Agenda: To consider and present the financial statements of the company for the fiscal year ended December 31, 2015; to consider and re-appoint kost, forer, gabbay & kasierer (a member of ernst & young global) as the company's independent registered public accounting firm until the next annual meeting and to authorize the company's board of directors to determine its compensation for the fiscal year ending December 31, 2016; to consider and re-election of the following company's currently serving directors: mr. howard b. rosen, dr. yaron daniely, dr. joao siffert, mr. daniel e. geffken, dr. aharon schwartz, and mr. arieh ben yosef; to consider and election of mr. ofer segev as a director and approval of his terms of compensation; to consider and election of ms. orli tori as a director and approval of her terms of compensation; to consider and approve grant of options to certain directors of the company; and to consider other matter also.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|